Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:462
  • Home
  • Print this page
  • Email this page
CASE REPORT
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 240-242

Interference of daratumumab with compatibility testing in blood bank


Department of Transfusion Medicine, Sakra World Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Siva Deepthi
Department of Transfusion Medicine, Sakra World Hospital, Bengaluru, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/GJTM.GJTM_10_19

Rights and Permissions

Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA, which is a CD38-targeted immunomodulatory drug, also cross-reacts with red cells and sensitizes them, causing difficulties and delay in the blood bank. To avoid delay in view of patient care, proper communication with blood bank professionals is required. We present a case of relapsed/refractory multiple myeloma in a 45-year-old male who required transfusions due to anemia and severe thrombocytopenia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed103    
    Printed2    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal